Active immunotherapy oncolytic virus therapy using HSV-1

Advances in Experimental Medicine and Biology

Volumn 746, Issue , 2012, Pages 178-186

  Todo, Tomoki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; G 207; INTERLEUKIN 12; INTERLEUKIN 18; M002; NV1042; ONCOLYTIC HERPES VIRUS; ONCOLYTIC HERPES VIRUS G47 DELTA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COLORECTAL CARCINOMA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENE CONSTRUCT; GENETIC ENGINEERING; GLIOBLASTOMA; GLIOMA; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNE RESPONSE GENE; IMMUNOSTIMULATION; NEUROBLASTOMA; NEUROLOGIC DISEASE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; SUBCUTANEOUS TISSUE TUMOR; UNSPECIFIED SIDE EFFECT; VIRUS INDUCTION;

BRAIN NEOPLASMS; GENETIC ENGINEERING; GLIOMA; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOTHERAPY, ACTIVE; MUTATION; ONCOLYTIC VIROTHERAPY; VIRUS REPLICATION;

HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 84862976494     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-3146-6_14     Document Type: Article

References (38)

1. Aghi M, Martuza RL. Oncolytic viral therapies-the clinical experience. Oncogene 2005; 24(52):7802-7816. (Pubitemid 41670681)
2. Zemp FJ, Corredor JC, Lun X et al. Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil. Cytokine Growth Factor Rev 2010; 21(2-3):103-117.
3. Todo T. Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci 2008; 13:2060-2064. (Pubitemid 351589234)
4. Markert JM, Medlock MD, Rabkin SD et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7(10):867-874. (Pubitemid 30303584)
5. Mineta T, Rabkin SD, Yazaki T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1(9):938-943.
6. Chou J, Kern ER, Whitley RJ et al. Mapping of herpes simplex virus-1 neurovirulence to gamma 34.5, a gene nonessential for growth in culture. Science 1990; 250:1262-1266. (Pubitemid 120031840)
7. He B, Chou J, Brandimarti R et al. Suppression of the phenotype of gamma(1)34.5- herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol 1997; 71(8):6049-6054. (Pubitemid 27304944)
8. Leib DA, Machalek MA, Williams BR et al. Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. Proc Natl Acad Sci USA 2000; 97(11):6097-6101. (Pubitemid 30367529)
9. Farassati F, Yang AD, Lee PW. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 2001; 3(8):745-750. (Pubitemid 32734253)
10. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988; 62(1):196-205.
11. Aghi M, Visted T, Depinho RA et al. Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene 2008; 27(30):4249-4254. (Pubitemid 351969906)
12. Markert JM, Liechty PG, Wang W et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and posttumor resection for recurrent GBM. Mol Ther 2009; 17(1):199-207.
13. Todo T, Martuza RL, Rabkin SD et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 2001; 98(11):6396-6401. (Pubitemid 32488248)
14. York IA, Roop C, Andrews DW et al. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8 T-lymphocytes. Cell 1994; 77(4):525-535.
15. Mohr I, Gluzman Y. A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J 1996; 15(17):4759-4766. (Pubitemid 26294594)
16. Wakimoto H, Kesari S, Farrell CJ et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009; 69(8):3472-3481.
17. Ino Y, Todo T. Clinical development of a third-generation oncolytic HSV-1 (G47) for malignant glioma. Gene Therapy and Regulation 2010 (in press).
18. Todo T, Rabkin SD, Sundaresan P et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 1999; 10(17):2741-2755.
19. Todo T, Rabkin SD, Chahlavi A et al. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum Gene Ther 1999; 10(17):2869-2878.
20. Toda M, Rabkin SD, Kojima H et al. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999; 10(3):385-393. (Pubitemid 29097317)
21. Nakano K, Todo T, Chijiiwa K et al. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters. Mol Ther 2001; 3(4):431-437. (Pubitemid 32509836)
22. Miller CG, Fraser NW. Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model. Mol Ther 2003; 7(6):741-747. (Pubitemid 36790250)
23. Goldsmith K, Chen W, Johnson DC et al. Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8 T-cell response. J Exp Med 1998; 187(3):341-348. (Pubitemid 28080063)
24. Hill A, Jugovic P, York I et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995; 375(6530):411-415.
25. Fruh K, Ahn K, Djaballah H et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995; 375(6530):415-418.
26. Galea-Lauri J, Farzaneh F, Gaken J. Novel costimulators in the immune gene therapy of cancer. Cancer Gene Ther 1996; 3(3):202-214.
27. Todo T, Martuza RL, Dallman MJ et al. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res 2001; 61(1):153-161. (Pubitemid 32095713)
28. Toda M, Martuza RL, Kojima H et al. In situ cancer vaccination: an IL-12 defective vector/ replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol 1998; 160(9):4457-4464. (Pubitemid 28217304)
29. Andreansky S, He B, van Cott J et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 1998; 5(1):121-130. (Pubitemid 28045078)
30. Hellums EK, Markert JM, Parker JN et al. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol 2005; 7(3):213-224. (Pubitemid 41079131)
31. Parker JN, Gillespie GY, Love CE et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 2000; 97(5):2208-2213. (Pubitemid 30134047)
32. Wong RJ, Patel SG, Kim S et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther 2001; 12(3):253-265. (Pubitemid 32163897)
33. Bennett JJ, Malhotra S, Wong RJ et al. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann Surg 2001; 233(6):819-826. (Pubitemid 32494563)
34. Parker JN, Meleth S, Hughes KB et al. Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther 2005; 12(4):359-368. (Pubitemid 40411195)
35. Shah AC, Prince KH, Parker JN et al. Serial Passage through human glioma xenografts selects for a δγ1 34.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors. J Virol 2006; 80(15):7308-7315. (Pubitemid 44092553)
36. Fukuhara H, Ino Y, Kuroda T et al. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res 2005; 65(23):10663-10668. (Pubitemid 41713331)
37. Ino Y, Saeki Y, Fukuhara H et al. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res 2006; 12(2):643-652. (Pubitemid 43166160)
38. Terada K, Wakimoto H, Tyminski E et al. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther 2006; 13(8):705-714.